Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMspire170: Cobimetinib + Atezolizumab vs Pembrolizumab in BRAF V600 Wild-Type Melanoma
NCT03273153Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of cobimetinib, atezolizumab in melanoma, sponsored by Roche. Started Dec 2017; status: terminated.
02
Drugs
cobimetinibatezolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03273153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273153.